KRAS and cancer: Sirtuin 2 (SIRT2), one of the mammalian nicotinamide adenine dinucleotide (NAD)-dependent lysine deacylases, catalyzes the removal of fatty acylation from KRAS4A leading to an increased endomembrane localization, interaction with A-Raf, and enhanced KRAS4A transforming activity, suggesting that SIRT2 may be therapeutic target for treating cancers associated with KRAS4A expression (Jing et al., 2017).